Tandem Diabetes (NASDAQ: TNDM) reported Q1 EPS of ($1.97), $1.37 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $234.4 million versus the consensus estimate of $220.3 million.

GUIDANCE:

Tandem Diabetes sees FY 2025 revenue of $997-1007 million, versus the consensus of $998.7 million.

Sales in the United States of approximately $725 million to $730 million.
Sales outside the United States of approximately $272 million to $277 million, which reflects a $15 million to $20 million headwind associated with the Company’s preparation for direct commercial operations in select countries.

Gross margin is estimated to be approximately 54% of sales for the full year.
Adjusted EBITDA margin(1) is estimated to be approximately 3% of sales for the full year.
Non-cash charges included in cost of goods sold and operating expenses are estimated to be approximately $115 million. This includes:

Approximately $95 million non-cash, stock-based compensation expense.
Approximately $20 million depreciation and amortization expense.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.